↓ Skip to main content

American College of Cardiology

Article Metrics

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction

Overview of attention for article published in JACC: Heart Failure, July 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#40 of 865)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
6 news outlets
twitter
86 tweeters
facebook
5 Facebook pages

Citations

dimensions_citation
107 Dimensions

Readers on

mendeley
124 Mendeley
Title
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
Published in
JACC: Heart Failure, July 2017
DOI 10.1016/j.jchf.2017.04.013
Pubmed ID
Authors

Scott D. Solomon, Adel R. Rizkala, Jianjian Gong, Wenyan Wang, Inder S. Anand, Junbo Ge, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe Martinez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. Van Veldhuisen, Faiez Zannad, Michael R. Zile, Akshay S. Desai, Victor C. Shi, Martin P. Lefkowitz, John J.V. McMurray

Abstract

The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective therapies that improve outcomes. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has been shown to benefit patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic effects in a phase II HFpEF trial. The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial comparing the long-term efficacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left ventricular ejection fraction ≥45%), New York Heart Association functional class II to IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Before randomization, all patients entered sequential single-blind run-in periods to ensure tolerability of both drugs at half the target doses (i.e., valsartan titrated to 80 mg bid followed by sacubitril/valsartan 49/51 mg [100 mg] bid). The primary outcome is the composite of cardiovascular death and total (first and recurrent) HF hospitalizations. PARAGON-HF will determine whether sacubitril/valsartan is superior to angiotensin receptor blockade alone in patients with chronic symptomatic HFpEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

Twitter Demographics

The data shown below were collected from the profiles of 86 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Unknown 123 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 18%
Unspecified 17 14%
Student > Ph. D. Student 17 14%
Student > Postgraduate 15 12%
Student > Doctoral Student 12 10%
Other 41 33%
Readers by discipline Count As %
Medicine and Dentistry 77 62%
Unspecified 24 19%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Nursing and Health Professions 4 3%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 10 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 91. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2019.
All research outputs
#184,720
of 13,721,158 outputs
Outputs from JACC: Heart Failure
#40
of 865 outputs
Outputs of similar age
#7,874
of 265,024 outputs
Outputs of similar age from JACC: Heart Failure
#4
of 27 outputs
Altmetric has tracked 13,721,158 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 865 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,024 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.